FindTrial
Sign In

Comparison of outcomes after HLA-haploidentical stem cell transplantation using posttransplantation cyclophosphamide (PTCY) and unrelated allogeneic stem cell transplantation.

Comparison of outcomes after HLA-haploidentical stem cell transplantation using posttransplantation cyclophosphamide (PTCY) and unrelated allogeneic stem cell transplantation. - AMED PTCY 17

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000033198
Enrollment
279
Registered
2018-06-29
Start date
2017-12-06
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients receiving HLA haploidentical stem cell transplantation with posttransplantation cyclophosphamide or unrelated stem cell transplantation.

Interventions

None listed

Sponsors

Hokkaido University Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients who receive HLA-haploidentical stem cell transplantation or unrelated stem cell transplantation between 2012 and 2015

Exclusion criteria

Exclusion criteria: Not applicable

Design outcomes

Primary

MeasureTime frame
Retrospective comparative analysis and a decision analysis—

Countries

Japan

Contacts

Public ContactJunichi Sugita

Hokkaido University Hospital Department of Hematology

sugitaj@med.hokudai.ac.jp011-706-7214

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026